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Abstract
Background: The symptom severity of a substantial group of schizophrenia patients (30–40%) does not improve
through pharmacotherapy with antipsychotic medication, indicating a clear need for new treatment options to
improve schizophrenia outcome. Meta-analyses, genetic studies, randomized controlled trials, and post-mortem
studies suggest that immune dysregulation plays a role in the pathophysiology of schizophrenia. Some anti-
inflammatory drugs have shown beneficial effects on the symptom severity of schizophrenia patients.
Corticosteroids are effective in various chronic inflammatory and autoimmune disorders. Prednisolone, a potent
glucocorticosteroid, has minor mineral-corticosteroid potencies and can adequately pass the blood–brain barrier
and its side effects and safety profile are well known. Therefore, the effect of prednisolone can be studied as a
proof of concept for immune modulation as a treatment for schizophrenia.
Methods/design: In total, 90 subjects aged 18–70 years and diagnosed with schizophrenia, schizoaffective disorder,
or schizophreniform disorder (Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) 295.x) or psychosis
not otherwise specified (NOS; 298.9) will be included. The time interval between the onset of psychosis and study
entry should not exceed 7 years. Patients will be randomized 1:1 to either prednisolone or placebo daily for a
period of 6 weeks in addition to a stable dose of antipsychotic medication. Study medication will be initiated at 40
mg for 3 days, after which it will be tapered down within 6 weeks after initiation, following inflammatory bowel
diseases treatment guidelines. Primary outcome is change in symptom severity, expressed as change in total score
on the Positive and Negative Symptom Scale (PANSS) from baseline to end of treatment. Cognitive functioning
(measured through the Brief Assessment of Cognition in Schizophrenia (BACS)) and change in Global Assessment
Functioning (GAF) and depressive symptoms as measured with the Calgary Depression Scale for Schizophrenia
(CDS) will be assessed, in addition to various immunological biomarkers. Secondary outcomes are a 4- and 6-month
follow-up assessment of PANSS, BACS, and GAF scores and immunological biomarkers. Additionally, a subgroup of
patients will be included in the magnetic resonance imaging (MRI) part of the study where MR spectroscopy and
structural, functional, and diffusion MRI will be conducted.
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Discussion: It is expected that prednisolone addition to current antipsychotic medication use will reduce symptom
severity and will improve cognition when compared to placebo.
Trial registration: ClinicalTrials.gov, NCT02949232 and NCT03340909. Registered 31 October 2016 and 14
November 2017. EudraCT-number 2014–000520-14 and 2017–000163-32.
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Background
Schizophrenia is a severe mental disorder with a world-
wide prevalence of around 1%, placing significant burden
on global health [1]. The introduction of antipsychotic
medications has improved the positive psychotic symp-
toms of schizophrenia patients [2]. However, schizophre-
nia remains a severe illness with high morbidity and
mortality rates [3]. Despite antipsychotic treatment,
negative symptoms seem especially persistent over time,
which negatively influences quality of life (QoL) [4].
Cognitive deficits are another factor underlying poor
QoL. Although not included in the diagnostic criteria
for schizophrenia, cognitive deficits are considered a
core feature of schizophrenia symptomatology [5]. Cog-
nition may also be a good predictor of long-term func-
tional outcome [6, 7]. A meta-analysis by Nielsen et al.
studying the effect of second generation antipsychotic
medication on cognition showed some trend level ef-
fects; however, none of the antipsychotic drugs showed a
positive uniform effect on cognition [8]. For this reason
there is a definite need to improve pharmacotherapy in
order to reduce symptom severity and counteract the
cognitive decline as well.
The accumulating evidence, derived from genetic,
post-mortem, epidemiological, and clinical studies, sup-
porting the role of immune dysregulation in the patho-
genesis of schizophrenia may provide an opportunity to
expand pharmacotherapeutic options. First, a significant
association with the major histocompatibility complex
(MHC) region, best known for its role in immunity, on
chromosome 6p21.3–22.1 was observed in a large
genome-wide association study (GWAS), including over
30,000 patients with schizophrenia [9]. An association
between MHC and psychosis was also described by Saito
and colleagues [10]. Next to this, increased expression of
complement 4 (C4), a protein originating from the MHC
region, has been found to be associated with schizophre-
nia. C4 plays a crucial role in the innate immune system
by swiftly identifying and eliminating pathogens [11].
Second, epidemiological studies support the theory
that the immune system is involved in schizophrenia. A
recent review by Jeppesen and Benros described the epi-
demiological evidence on bidirectional associations be-
tween autoimmune disorders and psychotic disorders
[12]. Patients with autoimmune disorders were found to
carry an increased risk to develop a psychotic disorder
and vice versa, suggesting that similar mechanisms are
involved in both disorders. Potential mechanisms and
risk factors found in both disorders are the presence of
neuronal surface antibodies, dysregulation of T and B
cells, and infections (viral or bacterial).
Third, microglia, the immune cells in the central ner-
vous system (CNS), have been suggested to play an im-
portant role in neurological function and cognition [13].
A recent meta-analysis on post-mortem brain studies in-
dicated that the number of activated microglia cells in
the brains of patients with schizophrenia is significantly
increased [14]. Microglia can be activated by a systemic
inflammatory trigger or by neurodegeneration, aging,
and stress [15]. Activated microglia cells can produce
free radicals, pro-inflammatory cytokines, and neuro-
toxic substances, which leads to cell death [16]. The acti-
vation of microglia cells provides a possible route by
which an inflammatory state in the brain could cause
increased grey matter (GM) loss and consequently
contribute to more severe negative and cognitive
symptoms. However, another meta-analysis found
lower levels of glial cell markers in first-episode
psychosis and schizophrenia patients in comparison
with healthy controls, suggesting a lower density of
immune cells and glial cells [17].
Fourth, immune dysregulation in psychotic disorder
patients might be reflected by abnormal levels of cyto-
kines and the presence of auto-antibodies in serum and
cerebrospinal fluid (CSF) [18]. A recent meta-analysis re-
ported significant increase in interleukin (IL)-6 and IL-8,
cytokines involved in inflammatory reactions, in schizo-
phrenia patients compared to healthy controls [19]. A
recent study found that symptom severity measured with
the Positive and Negative Syndrome Scale (PANSS) [20]
was strongly correlated with cytokine levels in the blood
that are involved in inflammation [21]. It was found that
symptom severity was positively associated with the
levels of pro-inflammatory markers such as IL-2R, IL-6,
and IL-8. Additionally, a large longitudinal study per-
formed in Finland found an association between high-
level C-reactive protein (CRP) values and the develop-
ment of schizophrenia [22]. Associations between CRP
levels and cognition in schizophrenia patients have also
been described in a recent systematic review [23]; higher
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CRP levels (> 3 mg/L) were associated with declined
cognitive performance (general intellectual ability, ab-
stract reasoning, working memory, semantic memory,
learning abilities, attention, mental flexibility, and pro-
cessing speed).
Altogether, there is accumulating evidence on the
presence of immune dysregulation in patients with
schizophrenia, justifying the research into augmenting
antipsychotic therapies with anti-inflammatory agents.
However, at this stage it is unclear whether an increased
pro-inflammatory status is characteristic for all patients
with schizophrenia; instead it might be applicable to a
specific subset of schizophrenia patients. This aligns with
the findings of Schwarz and colleagues, who studied mo-
lecular abnormalities in patients with schizophrenia
through multiplex immunoassay analyses and were able
to distinguish two subgroups based on predominant ab-
normalities in immune molecules or growth factors and
hormones [24].
Immune dysregulation in (a subset of) schizophrenia
patients may also result in structural changes in the
brain, which could be detected with MRI [25, 26]. These
brain changes are possibly present in the earlier stages of
the disease [27]. For instance, results from a large meta-
analysis suggest that the initiation of white and grey
matter (WM and GM) loss is seen in schizophrenia pa-
tients before the first psychotic episode [28]. Moreover,
the GM and WM loss progresses over the course of the
illness. In several studies, GM loss in the first 5 years
after diagnosis is associated with poor cognitive func-
tioning and bad outcome [29]. If immune modulation
can reduce loss of the GM, it would be expected to be
most effective in the first years of illness. Subsequently,
both symptom severity and long-term outcome could be
improved. However, the available immune studies have
focused mainly on chronically ill patients with psychosis
[30]. It is important, therefore, to investigate the efficacy
of administering a broad-acting, potent immune sup-
pressive agent, especially early in the course of the dis-
ease as this may prevent neuronal damage caused by
low-grade inflammatory processes in the brain.
Anti-inflammatory drugs that could be used to treat
inflammation in psychotic disorder patients include glu-
cocorticosteroids and non-steroidal anti-inflammatory
drugs (NSAIDs). Broberg and colleagues studied the risk
of developing schizophrenia after glucocorticosteroid use
in a large Danish population and found that glucocorti-
costeroid use is associated with an increased risk of de-
veloping schizophrenia [31]. The association might be
confounded by the severity of the underlying inflamma-
tory condition, however, as more severe inflammation
may be expected to require more potent anti-
inflammatory interventions. Further, it was described
that short-term treatment with glucocorticosteroids
might be effective in treating psychotic episodes, espe-
cially in patient subgroups in which increased inflamma-
tion is a likely cause of the psychotic symptoms. A
meta-analysis by Çakici and colleagues contained 56 ran-
domized clinical trials (RCTs) in which agents with anti-
inflammatory potential were studied in patients with
schizophrenia [32]. Several anti-inflammatory agents
were found to significantly improve schizophrenia symp-
toms with medium to large effect sizes; aspirin (ES =
0.3), estrogens (ES = 0.78), minocycline (ES = 0.4), and
N-acetylcysteine (NAC; ES = 1.0). Some agents were
found to have a beneficial effect on cognition: minocy-
cline (attention, executive functioning, and memory),
davunetide (verbal learning and memory), and NAC (at-
tention, memory, and executive functioning). The het-
erogeneity of the cognitive tests used in the study made
it impossible to create a quantitative review. Further-
more, the patient samples were heterogeneous, with dur-
ation of illness as a potential moderator. It was
concluded, therefore, that the effect of immune modula-
tion may be largest in patients with recent onset schizo-
phrenia, as the hypothesized pro-inflammatory status in
the brain may be most pronounced during and shortly
after disease onset [32].
Although the indications of immune involvement in
schizophrenia are accumulating, it is still not possible to
reliably specify the exact components of the immune
system involved [33]. This leads to uncertainty in the
choice of targets and treatment options. Corticosteroids
are potent immune modulating agents that target many
different aspects of both the innate and the adaptive im-
mune responses. So far, no data exist on the effective-
ness of corticosteroids in symptomatology and cognitive
deficits in schizophrenia. However, a positive effect on
cognition was demonstrated in patients with multiple
sclerosis (MS) [34, 35], suggesting that corticosteroids
may prevent cognitive deterioration in diseases with a
neuroinflammatory component.
Prednisolone is a broad spectrum glucocorticosteroid
which interferes with almost all primary and secondary
immune cells, including monocytes, microglia cells, T
cells, and granulocytes [36]. Furthermore, in contrast to
most glucocorticosteroids, prednisolone can easily pass
the blood–brain barrier, which is a prerequisite to in-
duce immune modulation in the brain. Finally, there is
ample clinical experience with prednisolone and its side
effect and safety profiles are well known, as it has been
administered for short-term and chronic use in several
forms in various conditions for decades [37]. Therefore,
treatment with prednisolone can be used as a proof of
concept to investigate the possibility of immune modula-
tion as a treatment for schizophrenia. Neuropsychiatric
side effects of prednisolone, such as depression, mania,
psychosis, and suicidal ideation, have been reported.
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These events are dose dependent, as shown in a meta-
analysis in which all corticosteroid-induced adverse
events reported in all available studies have been de-
scribed; hazard ratios for all neuropsychiatric side ef-
fects, except panic disorder, did not exceed 1.3 for
dosages up to 40mg prednisolone [38]. As prednisolone
carries the risk for neuropsychiatric side effects, extra
safety rules are necessary when testing its efficacy as




The study procedures described in this paper are com-
parable to procedures described in a previously pub-
lished paper by our group related to another
randomized clinical trial (RCT) [40]. However, there are
essential differences between both studies, such as treat-
ment duration, duration of the trial itself, and an inter-
view used to determine the diagnosis of the participant
as well as the intervention.
This study, being a proof of concept trial, was designed
as a double-blind placebo-controlled trial to be able to
differentiate between clinical effects of prednisolone
addition and placebo effects. Prednisolone or placebo is
provided in addition to current antipsychotic medication
as it is not the intention to replace existing antipsychotic
treatments. Finally, by applying the placebo arm and ur-
ging treating physicians to keep the antipsychotic dose
as stable as possible during the 6-week period, the effect
of prednisolone addition can be measured.
In this study, 90 patients with schizophrenia, schizoaf-
fective disorder, schizophreniform disorder, or psychotic
disorder not otherwise specified (NOS) will be included;
patients are aged 18–70 years and have a time interval be-
tween the onset of psychosis and study entry not exceed-
ing 7 years. Patients will continue their antipsychotic
medication and (if applicable) other psychotropic drugs
throughout the treatment period of 6 weeks. Doses are
preferably kept stable, but dose adjustments of up to 25%
of the initial dose are allowed. Changes in dosage of anti-
psychotic medication or benzodiazepines of 25% or more
(relative to the baseline visit), will be regarded as a second-
ary outcome measure.
For this proof of concept study, a treatment period of
6 weeks was considered appropriate. We hypothesize
that if prednisolone carries the expected effect, this will
be apparent within this period of time. The study does
not intend to assess the therapeutic potential of prednis-
olone as a possible augmentation therapy for these pa-
tients. Rather, the results may strengthen the case for
immune-modulatory treatment and encourage further
research in this direction.
Aims
This study aims to investigate the effect of prednisolone
augmentation to antipsychotic pharmacotherapy in pa-
tients with a psychotic disorder. The primary objective
of this study will be the change in symptom severity
(PANSS) between baseline and end-of-treatment (6
weeks treatment). Secondary objectives include changes
in symptom severity in the follow-up phase, cognition,
depressive symptoms, global functioning, prediction of
treatment response to prednisolone therapy using im-
mune markers (blood samples), and insight into psych-




In total, seven health care centers (academic hospitals
and community clinics) will recruit patients for this trial;
three Dutch centers, one Belgian center, and three Nor-
wegian centers. Patient clinic lists will be screened at all
participating sites for potential patients. Additionally,
potential patients will be referred by other healthcare
centers and researchers from other trials that are collab-
orating with the participating centers involved in this
trial. In Norway eligible patients will be referred by their
treating psychiatrists and physicians.
Allocation
All 90 patients will be randomized 1:1 to either prednisol-
one or placebo for 6 weeks study medication use, in
addition to their current antipsychotic medication as pre-
scribed by their treating physician. A randomization list has
been created independently by the data management team
of the Julius Center, University Medical Center, Utrecht
(The Netherlands and Belgium) and by biostatisticians at
the University of Bergen, Bergen (Norway). Study medica-
tion kits were manufactured based on this randomization
list. A web-based application (https://www.juliuscentrum.
nl/random/ in the Netherlands and Belgium) and a paper
randomization list are used by blinded study team members
to allocate the applicable kit number to each patient.
Randomization was stratified for country, center, and
gender.
The study staff will not have access to the trial treat-
ment randomization codes. These will be stored in the
pharmacy in the University Medical Center Utrecht
(The Netherlands), Ziekenhuis Netwerk Antwerpen
(Belgium), and Haukeland University Hospital (Norway)
in case emergency unblinding is needed. In the case of
serious adverse events (SAEs) where knowledge regard-
ing the assigned treatment is important to decide on
medical management of the emergency event, unblind-
ing is permitted.
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This study is a double-blind placebo controlled trial in
which both the patients and the study team members
are blind to treatment allocation. None of the study
team members have access to the randomization codes.
The study physicians who are reviewing laboratory re-
ports for safety purposes are prohibited from collecting
any study data for those individual patients. The labora-
tory results are stored in a location which is not access-
ible to the study team members conducting protocol
procedures.
Inclusion criteria
1. A DSM-IV-TR diagnosis of 295.x (schizophrenia,
schizophreniform disorder, or schizoaffective dis-
order) or 298.9 (psychosis NOS).
2. Onset of psychosis no longer than 7 years ago.
3. Minimum total PANSS score of 60.
4. Aged 18–70 years.
5. Patients are treated with antipsychotic medication
(stable dosage for at least 3 weeks).
6. Written informed consent is obtained.
7. Female patients of childbearing potential need to
utilize a proper method of contraception
(contraceptive pill, vaginal ring, hormonal patch,
intrauterine device, cervical cap, condom,
contraceptive injection, diaphragm) in case of
sexual intercourse during the study.
Additional inclusion criteria for patients included in
Norway are listed in Additional file 1.
Exclusion criteria
1. Presence of any contraindications of prednisolone
as reported in the summary of product
characteristics (SPC)
2. Presence of diabetes mellitus or random glucose
levels exceeding 11 mmol/L at screening in a non-
fasting condition or 7 mmol/L in a fasting condition,
severe heart failure, severe osteoporosis, or systemic
fungal infections
3. Body mass index (BMI) of > 30.0
4. Current or chronic use of systemic
glucocorticosteroids (temporary use is permitted, if
stopped 1 month before start of treatment trial)
5. Chronic use of NSAIDs, defined as daily use during
more than 2 months; intermittent use is permitted
if stopped at least 1 month before start of treatment
trial
6. Pregnancy or breast-feeding—a urine pregnancy test
will be performed at screening
7. Concurrent use of certain types of medication:
a. Carbamazepine, riphampicine, primidone,
barbiturates, and phenytoine
b. HAART medication (both HIV protease
inhibitors and (non)-nucleoside reverse
transcriptase inhibitors), especially efavirenz,
ritonavir, and lopinavir
c. Telaprevir and boceprevir in treatment of
hepatitis C
Additional exclusion criteria for patients included in
Norway are listed in Additional file 1.
Interval assessments
In total, 11 visits will be conducted throughout a period
of 1 year. The patients are using study medication for 6
weeks and will be followed up for another 46 weeks. The
informed consent procedure and the eligibility check will
be conducted during the screening visit. When the pa-
tient is eligible for study participation, the patient will be
randomized to either prednisolone or placebo. During
the 6 weeks of study medication intake, the patient will
be reviewed weekly by a study physician for adverse
events. The symptom severity, which is the primary out-
come of this study, will be measured by conducting the
commonly used PANSS interview, assessed by a trained
researcher. Additionally, the Global Assessment Func-
tioning (GAF) score [41], the Calgary Depression Scale
for Schizophrenia (CDS) score [42], drug and alcohol
use, and cognition by using the Brief Assessment of
Cognition in Schizophrenia (BACS) score [43] will be
measured. Blood will be withdrawn at five occasions
throughout the study for metabolic and immunological
measurements. The patients in Norway will be invited to
the optional MRI procedures. An overview of the assess-
ments per visit can be found in Table 1.
Training and inter-rater reliability
All involved researchers will be trained in the PANSS
interview by an experienced PANSS trainer, using in-
structional videos and assessment of a test video in a
classroom setting or by a training program at the PANSS
institute (panss.org). After passing an exam, researchers
can perform PANSS ratings for this study. PANSS raters
will be assigned to patients in order to limit the bias in
PANSS assessment in patients. Proper conduct of The
Comprehensive Assessment of Symptoms and History
(CASH; the Netherlands and Belgium; demographics, al-
cohol, and drugs only) interview [44], Mini International
Neuropsychiatric Interview 5.0.0 Plus (M.I.N.I. 5.0.0
Plus) [45], and cognitive testing will also be trained by
experts. Study team members will be carefully selected
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and extensively informed and trained regarding Good
Clinical Practice (GCP).
Treatment
All patients included in the study will use the study
medication in addition to their current antipsychotic
medication as prescribed by their treating physician at
the time of inclusion. Study medication kits were pre-
pared by ACE Pharmaceuticals (The Netherlands and
Belgium) and Kragerø Tablettproduksjon AS (Norway).
They were provided with a randomization list indicating
which kit number should contain which treatment. The
pharmaceutical company responsible for manufacturing
the study medication ensured that the tablets are indis-
tinguishable in appearance, shape, smell, mass, and taste.
Study medication will be tapered-off within 6 weeks in
the following schedule: 40 mg/day for 3 days and 30 mg/
day for 4 days, followed by a decrease of 5 mg/day per
week during the remaining 5 weeks; in the second week,
patients will use 25 mg/day, in the third week 20 mg/day,
etc. In the last week the patients will only take prednis-
olone on days 1–3 and day 5 and 7; a tapering scheme
in line with the treatment guidelines for inflammatory
bowel diseases (2008). Each study medication kit con-
sists of six weekly boxes, each containing all dosages for
one week, in which the study medication tablets are
sorted according to the tapering-off schedule. Each
weekly box is labeled in line with Annex 13 of Clinical
Trial Directive.
To prevent loss of bone mass, we will provide calcium
supplementation (calciumcarbonate 500 mg daily) and
vitamin D supplementation (cholecalciferol 400 IU
daily). Pantroprazole will be actively provided to patients
with a history of ventricular/duodenal ulcer.
Outcome variables
Primary outcome variables
Clinical outcome measure Our main study parameter
is overall symptom severity as measured with the PANSS
total score.
Secondary outcome variables
Symptom severity Secondary study parameters include
PANSS total scores 4, 6, and 12months after start of the
treatment. Furthermore, general functioning will be eval-
uated using the GAF comparing patients treated with
prednisolone versus placebo.
Cognitive assessment Neurocognitive functioning as
measured with the BACS will be used to measure the
possible improvement over the treatment and the 6-
month follow-up period. The BACS was chosen as the
neurocognitive measure due to its repeatability as well
as the short assessment time (35 min), which is expected
to lead to higher completion rates and fewer missing
data. The BACS has been developed for assessing the
domains of cognitive functioning in schizophrenia trials
[43]. It consists of the following domains:
1. Verbal memory: List Learning
2. Working memory: Digit Sequencing Task
3. Motor speed: Token Motor Task
4. Verbal fluency: Category Instances
5. Verbal fluency: Controlled Oral Word Association
Test
6. Attention and speed of information processing:
Symbol Coding
7. Executive functions: Tower of London
Laboratory assessments Immunological and metabolic
parameters will be assessed four times over the 1-year
study period. We will investigate inflammatory processes
that may be involved in a subpopulation of patients with
psychotic disorders using prednisolone augmentation
[33]. To investigate immunological biomarkers that pre-
dict treatment response to prednisolone therapy, we will
collect serum and RNA of all patients at baseline and 3,
6, and 26 weeks after the start of the study medication
use. The laboratory assessments will contain the follow-
ing analyses:
1. Multiplex immunoassay
2. Infectious disease profiling
3. Flow cytometry
4. Selective reaction monitoring (SRM)
Brain imaging (optional in Norway) Information re-
garding the brain imaging part of the study conducted in
Norway can be found in Additional file 2.
Other objectives
Severity of depression will be assessed and compared be-
tween groups using the CDS. The need to adjust current
antipsychotic medication by 25% or more is compared
between groups. Finally, safety data will be assessed by
comparing incidence (number and percentage of sub-
jects with at least one occurrence) of key SAEs and sus-
pected unexpected serious adverse reactions (SUSARs)
between both groups, e.g., hospitalizations.
Safety assessment
Safety measurements
At each visit a study physician (psychiatrist or psychiatry
resident) will review the possible adverse events (espe-
cially neuropsychiatric side effects), medication use, and
any contraindications for prednisolone use. After the
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screening visit, the blood results will be reviewed by a
study physician regarding the inclusion and exclusion
criteria. After the baseline visit at which patients start
study medication, safety parameters will be checked by a
study physician who is not conducting any other proto-
col assessment. Based on blood assessment, presence of
adverse events, and contraindications for prednisolone
use, it will be determined if it is still safe to use the study
medication.
Stopping rules
Several events that may jeopardize the patient’s health
will prompt clinicians to end the study and start tapering
the patient off the study medication immediately in line
with the treatment guidelines for inflammatory bowel
diseases (2008). These events include the patient
developing:
 A (fasting) blood glucose exceeding 7.0 mmol/L; in
case a non-fasting glucose level was determined, a
blood glucose level exceeding 11 mmol/L
 Suicidal ideations assessed by the CDS, the following
cut-off are applicable based on item 8: Suicidal idea-
tions within the CDS
◦ Score of 0: no action (no suicidal ideation)
◦ Score of 1: consult with clinician (passive suicidal
ideation)
◦ Score of 2/3: potential cause to stop study
medication treatment—consult with clinician
(active suicidal ideation)
 A PANSS positive subscore which increases by 10 or
more points without a clear reason (i.e., medication
non-adherence)
 PANSS item G6 (depression) exceeding a score of 4
 The need for coercive treatment
 Pregnancy
 Oral systematic infectious disease
Adverse events
Any undesirable experience occurring in a subject dur-
ing the study is defined as an adverse event (AE), regard-
less of any relatedness to the study medication. All AEs
reported spontaneously by the subject or observed by
the investigator or study team members conducting the
visit will be recorded. AEs will be checked by a study
physician every visit by asking an open question about
how the patient is doing and if the patient was suffering
from any AE. Furthermore, the study physician will as-
sess a standardized questionnaire which includes all po-
tential prednisolone-related AEs. If an AE requires
follow-up, the study physician will inform the general
practitioner, will examine and monitor the AE him/her-
self, or, if necessary, will liaise with a medical specialist.
In case SAEs have occurred, the applicable authorities
will be informed as described in the study protocol fol-
lowing the guidelines. In line with local laws and regula-
tions, participant insurance is in place in case any harm
caused by the trial procedures is experienced by the
participants.
Power calculation and statistical analysis
A two group t-test with a 0.050 two-sided significance
level will have 80% power to detect an effect size of
0.610 when the sample sizes in the two groups are 44
and 44, respectively (a total sample size of 88; text gen-
erated by nQuery Advisor). Subsequently, the sample
size can be reduced by the data with an Ancova instead
of analyzing a t-test [46]. The level of reduction depends
on the correlation (r) between baseline and follow up
measurements: N-ANCOVA = ((1 − r2) × N t-test) + 1.
From a previous study in this hospital (OPTiMiSE trial)
where a PANSS was performed at baseline and after 6
weeks, r = 0.48 was found. Therefore, N-ANCOVA = ((1
− 0.482) × 88) + 1 = 68.7248. Lastly, we expect a consid-
erable number of drop outs. Assuming a drop-out rate
of 30%, the definitive sample size is calculated at 68.7248
× 1.3 = 89.34224, which makes a total of N = 90 patients.
Statistical analyses for baseline characteristics and the
outcomes regarding symptom severity, global function-
ing, depressive symptoms, and cognition will be per-
formed in IBM SPSS Statistics version 25.0 [47]. A
summary of the baseline characteristics will be created
in order to assess baseline differences across the treat-
ment groups. Normal distributed data will be expressed
as means and standard deviations, and categorical data
will be expressed as percentages. The baseline character-
istics of the prednisolone and placebo group will be
compared and tested with a t-test (for continuous vari-
ables) and a Chi-square test (for categorical variables). In
this study we will use a mixed model analysis. Since we
do not estimate a linear change in this analysis, the in-
crease in efficiency compared to the analysis of covari-
ance and therefore the reduction in sample size will not
be immense and this calculation will suffice. The mixed
model analysis will allow us to use the data of the dis-
continued patients as it takes into account all observa-
tions. This analysis will be used for the objectives
regarding symptom severity, global functioning, depres-
sive symptoms, cognition, and MRI. As stratification was
performed for gender, center, and country, these vari-
ables will be used as covariates in the analyses in
addition to variables that are significantly different be-
tween treatment groups as well as the unused pills (per-
centage over the whole treatment period) to take into
account compliance with study medication.
Statistical analysis for the prediction of treatment re-
sponse to prednisolone therapy using immune markers will
be conducted using R software. Protein concentrations
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before and after treatment with prednisolone and placebo
will be compared using mixed effects analysis of covariance
adjusted for covariates significantly differing between the
groups. Association of clinical outcomes with baseline levels
of selected biomarkers in the prednisolone treatment group
(i.e., prediction of treatment response) will be assessed
using fixed effects analysis of covariance with adjustment
for significant covariates. Sensitivity analyses will be con-
ducted by excluding covariates from the analysis of covari-
ance models and, if applicable, including outliers.
Study procedures
Screening visit
Potential study participants will be informed regarding
all study procedures. They will be provided with an in-
formation letter and will be given sufficient time to read
all information, ask any questions of the investigator,
and liaise with family and friends. Participation in this
study is completely voluntarily. When a potential study
participant agrees to take part in this study, written in-
formed consent will be obtained by the study physician.
After the informed consent procedure has been com-
pleted, eligibility criteria will be checked to assess the
patient’s eligibility for participation within the study.
The M.I.N.I. 5.0.0 Plus will be assessed to confirm the
inclusion diagnosis. Additionally, the PANSS and GAF
will be assessed, which both relate to the past week.
Additionally, several demographical and clinical variables
will be assessed, including date of birth, sex, educational
level, prior psychiatric disorders, duration of untreated
psychosis, and use of drugs and alcohol. The CASH will
be used in the Netherlands and Belgium to document
the sociodemographic data and drug and alcohol use,
whereas similar forms will be used in Norway. Further-
more, the use of concomitant medication, medical his-
tory, and current medical conditions will be recorded.
The maximum period between screening visit and base-
line visit is 12 weeks. If the patient uses co-medication at
the screening visit, which is not allowed, it can be
washed out during this period. Additionally, physical
examination will be conducted by a study physician, in-
cluding BMI, blood pressure, and temperature. Any ab-
normality will be discussed with the patient’s treating
physician. To rule out pregnancy in female patients, a
urine pregnancy test will be performed. Electrocardio-
gram (ECG) examination will be conducted in all pa-
tients above 60 years old, patients with congenital heart
defects, and patients with plausible familial heart disor-
ders and patients with a medical history of syncope, car-
diac arrythmias, use of antiarrythmic medication, angina
pectoris, heart failure, (recent) myocardial infarction, or
myocarditis (Cahn et al. 2008). Signs of lipodystrophy
will be monitored. Additionally, blood will be drawn to
determine and rule out hyperglycemia as well as signs of
systemic infection as these are special warnings for the
use of prednisolone. Additionally, several blood parame-
ters (blood differentiation, electrolytes, and thyroid, liver,
and renal function) will be checked at screening to iden-
tify other serious diseases. Patients need to meet all in-
clusion criteria and none of the exclusion criteria to be
regarded as eligible to participate.
Baseline visit
At baseline, PANSS and GAF will be administered, in
addition to the CDS and the BACS. If the time between
screening and baseline is less than 2 weeks, the PANSS
will not be repeated at baseline. Additionally, the pres-
ence of any exclusion criteria for the current study will
be checked as well as suicidal ideation. Subsequently, the
patient will be randomized and the study medication will
be dispensed for the first time. Patients will be instructed
on medication use with regards to contraindicated co-
medications. Blood will be drawn to assess immuno-
logical parameters. A study letter will be send to the
treating psychiatrist, general practitioner, and pharma-
cist regarding the patient’s participation.
Treatment visits
After the baseline visit, patients will be assessed weekly
for 6 weeks. During various visits, a trained study team
member will interview them using the PANSS, GAF
(every other week; visits 2, 4, 6, and 8) and CDS ques-
tionnaires (weekly). At each visit, the presence of sui-
cidal ideation is carefully monitored. Co-medication use
will be noted as well as side effects and treatment com-
pliance. Except for visit 8, study medication will be dis-
pensed during each visit during the treatment period.
Alcohol and drug use will be assessed using the alcohol/
drug use section of the CASH during visits 5 and 8 in
the Netherlands and Belgium, whereas similar forms will
be used in Norway. At visits 2, 5, and 8 blood draws
intended for immunological assessments will be per-
formed. After the blood draw the patients need to re-
main within the hospital (when possible) until the
laboratory values are checked by a physician in case
follow-up treatment is necessary. Furthermore, pill boxes
are returned to the study centers each week to assess
compliance with study medication. Cognitive testing will
take place at the end (6 weeks) of the treatment period.
Follow-up visits
After 16, 26, and 52 weeks (relative to baseline), follow-
up visits will take place, during which the PANSS, CDS,
and GAF are assessed. Additionally, the current use of
medication and adverse events will be noted. At visit 10,
blood will be drawn to assess immunological parameters
and the BACS will be repeated once more.
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Patient safety and emergency unblinding
The participants’ treating physicians remain responsible
for the day-to-day treatment. Prednisolone has minor
mineral-corticosteroid potencies and is able to ad-
equately pass the blood–brain barrier. The side effects
and safety profile of prednisolone are well known. The
principal investigator will be responsible for the med-
ical and safety concerns related to study participation.
Study members can be contacted at the telephone
number provided on the emergency card provided the
first time the study medication is dispensed and the
letters patients receive during the study. This emer-
gency card includes a telephone number from the
pharmacy in case emergency unblinding is necessary
outside office hours.
Emergency unblinding is only permitted when neces-
sary for the subject’s emergency treatment at the investi-
gator’s discretion or when required by local laws or
regulations. Sealed unblinding envelopes, accessible 24/
7, are used for emergency unblinding situations. For
each medication set, an unblinding envelope is sent to
the applicable hospital pharmacy or hospital department,
containing the name of the treatment in each specific
study medication kit. The pharmacist or representative
performing the unblinding will always request details
from the study physician regarding patient information
and checks whether the unblinding has consequences
for the treatment of the adverse events causing the
emergency unblinding.
Patient withdrawal
Subjects can quit study participation at any time for any
reason without any consequences if they wish to do so.
The investigator can decide to withdraw a subject from
the study for urgent medical reasons.
Reasons to terminate a patient’s participation include
but are not limited to the following:
 The patient withdraws her/his consent
 Intolerance to the study medication
 Start of the use of NSAIDs, HAART, telaprevir,
boceprevir, riphamicine, primidone, barbiturates,
and phenytoine
 Administration of a live vaccine is needed
 Any of the stopping rules provided in section 2.10
In case a patient or the investigator decides to ter-
minate a patient’s participation, the patient needs to
be followed until the patient has completely tapered-
off the study medication. This tapering-off scheme
will be decided by a study physician based on the
patient’s situation. If needed, the study physician will
liaise with a medical specialist (e.g., endocrinologist).
Incentives
The patients will be compensated for the time and ef-
fort related to their participation in this trial. Patients
in The Netherlands and Belgium will receive 25 euros
per completed study visit and all travel expenses will
be reimbursed. Patients in Norway will receive 200
Norwegian kroners for their time investment and
travel expenses.
Data collection, management, and dissemination of the
results
Data will be collected on paper during the study visits
and will be inserted in an electronic case report form
(eCRF). The paper documentation will be stored in a
locked cabinet, accessible for authorized personnel only.
Data collected during visits with study participants will
be pseudonymized and will be treated as confidential.
The link between the patient identifiers and the subject
study number is documented on a subject identification
code list, which is only accessible for authorized study
team members.
Once all data have been inserted in the eCRF and veri-
fied by the monitor, the data will be signed off by the
principal investigator. Hereafter the eCRF will be locked,
after which the data in the eCRF cannot be changed.
Data managers will create the final database. The final
anonymized database will be shared with the Stanley
Medical Research Institute for the data obtained in the
Netherlands and Belgium. Specific data management
procedures can be provided by the trial coordinator on
request.
The results of this study will be presented as abstracts,
oral presentations, or posters, as well as publication in
an international peer-reviewed journal. Patients who re-
quested to be informed regarding the outcome of the
trial will receive an information letter containing the
overall outcome of the study.
Ethical and regulatory standards
Medical ethics review board
Ethics approval was obtained from the research and eth-
ics committee of the University Medical Center Utrecht
(UMCU), the Netherlands, protocol number 14–110,
Ziekenhuis Netwerk Antwerpen (ZNA), Belgium and
Haukeland University Hospital, Norway, protocol num-
ber 2017/620. Approval was also obtained from the Nor-
wegian Medicines Agency. The trial is registered in the
ClinicalTrails.gov database (identifier NCT02949232 for
the Netherlands and Belgium and NCT03340909 for
Norway) and the European Clinical Trials Database
(EudraCT number 2014–000520-14 for the Netherlands
and Belgium and 2017–000163-32 for Norway).
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Data and safety monitoring board
The safety of the study will be judged by an independent
committee of experts (data and safety monitoring board)
on a regular basis, at a frequency of at least once a year.
The members of this board will have access to all safety
and progress information (e.g., inclusion and drop-out
rates). If deemed necessary, the DSMB members may re-
view the unblinded study data. The DSMB will meet
each time after ten additional patients are recruited, but
meetings may be more frequent depending on trial
events causing safety concerns, the enrolment rate
(much slower or faster than anticipated), or when the
DSMB deems this to be appropriate for other reasons.
The DSMB may suggest changes to the protocol or pro-
vide an altered judgment of feasibility if information
from the annual safety report or new information about
the study medication becomes available. No interim ana-
lyses are planned. The tasks and responsibilities of the
DSMB, as well as premature termination criteria, are de-
scribed in a separate DSMB charter, which can be pro-
vided by the trial coordinator on request.
Declaration of Helsinki
The study will be conducted in accordance with this
protocol as well as the principles of the Declaration of
Helsinki (64th WMA general assembly; Fortaleza, Brazil,
October 2013), the ICH-GCP guidelines, and other ap-
plicable laws and regulations.
Discussion
This study was developed to explore pharmacotherapy
options with an anti-inflammatory agent to improve
both clinical symptoms and cognition in patients with a
psychotic disorder. Prednisolone was chosen due to its
potent, broad acting immune modulating working mech-
anism. The potential positive effect of prednisolone aug-
mentation to current antipsychotic medication use will
be investigated in this study. Given its potential to re-
duce microglia activity in the brain and lower activity of
both the innate and the acquired immune system, it is
expected that prednisolone will lower the symptom se-
verity (decrease in PANSS total and subscores) and will
improve cognition (especially attention, executive func-
tioning, and verbal memory) and global functioning in
comparison to placebo.
If we are to find efficacy of prednisolone addition, a
second step is to investigate exactly which immune com-
ponents mediate this effect. For this purpose, blood is
drawn at regular intervals to monitor baseline values
and changes in inflammatory blood markers. Positive ef-
fects on symptoms and cognition have been demon-
strated from corticosteroids used to treat MS, traumatic
brain injury, and stroke, disorders in which an immune
component has clearly been described [48]. A negative
finding in the current study might mitigate our enthusi-
asm to test other anti-inflammatory drugs as augmenta-
tion for treatment options. Corticosteroids have been
described to elicit psychiatric symptoms. Therefore,
medication is given in a moderate dose and medical as-
sessments are frequently performed to screen for suicid-
ality and other safety issues. We expect that the results
of this study, be it positive or negative, will give strong
direction to the emerging field of immune-psychiatry for
the treatment of psychosis.
Trial status
The study is active and currently recruiting patients. Re-
cruitment started in March 2015. The recruitment in
The Netherlands and Belgium was completed end of
2018 and the final assessments were performed in 2019.
Recruitment in Norway will be completed by the end of
2021. The final assessments in Norway will be con-
ducted at the end of 2022. The following protocol ver-
sions are currently used; protocol version 9.0 dated 19
December 2018 in the Netherlands, protocol version 8.0
dated 28 September 2018 in Belgium, and protocol ver-
sion 6.0 dated 04 January 2019 in Norway.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04365-4.
Additional file 1. Additional eligibility criteria for patients included in
Norway.
Additional file 2. Brain imaging (optional part of the study in Norway).
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